Article
Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201.
Journal of neuro-oncology - 1 Oct 2019
Chi Andrew S, Tarapore Rohinton S, Hall Matthew D, Shonka Nicole, Gardner Sharon, Umemura Yoshie, Sumrall Ashley, Khatib Ziad, Mueller Sabine, Kline Cassie, Zaky Wafik, Khatua Soumen, Weathers Shiao-Pei, Odia Yazmin, Niazi Toba N, Daghistani Doured, Cherrick Irene, Korones David, Karajannis Matthias A, Kong Xiao-Tang, Minturn Jane, Waanders Angela, Arillaga-Romany Isabel, Batchelor Tracy, Wen Patrick Y, Merdinger Krystal, Schalop Lee, Stogniew Martin, Allen Joshua E, Oster Wolfgang, Mehta Minesh P
Abstract excerpt
BACKGROUND: H3 K27M-mutant diffuse midline glioma is a fatal malignancy with no proven medical therapies. The entity predominantly occurs in children and young adults. ONC201 is a small molecule selective antagonist of dopamine receptor D2/3 (DRD2/3) with an exceptional safety profile. Following up on a durable response in the first H3 K27M-mutant diffuse midline glioma patient who received ONC201 (NCT02525692),...
Read the complete abstract on PubMedTopics
- Adolescent
- Adult
- Antineoplastic Agents